For Millions, an Upcoming FDA Meeting on a New Alzheimer’s Drug is More Than Just News—It’s Hope
WASHINGTON, DC – An independent advisory committee for the Food and Drug Administration (FDA) will meet on July 13 to review a new Alzheimer’s drug, a decision that holds profound implications for millions of patients and their families.